Cantor Fitzgerald Cuts Nyxoah (NASDAQ:NYXH) Price Target to $6.00

Nyxoah (NASDAQ:NYXH) had its price target reduced by Cantor Fitzgerald to $6.00 in a research report report published on Monday, MarketBeat Ratings reports. They currently have an overweight rating on the stock.

A number of other analysts have also weighed in on NYXH. Robert W. Baird set a $2.31 price objective on Nyxoah in a research report on Thursday, August 6th. Oppenheimer set a $4.00 target price on Nyxoah in a research note on Thursday, August 6th. Wall Street Zen downgraded Nyxoah from a “hold” rating to a “sell” rating in a report on Sunday, August 9th. Stifel Nicolaus reduced their price target on Nyxoah from $5.00 to $3.00 and set a “hold” rating on the stock in a research report on Wednesday, June 17th. Finally, Weiss Ratings lowered Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Nyxoah presently has a consensus rating of “Hold” and a consensus price target of $4.26.

Nyxoah Stock Up 3.1%

Shares of NASDAQ:NYXH opened at $1.65 on Monday. The firm has a market capitalization of $63.95 million, a PE ratio of -0.65 and a beta of 1.62. Nyxoah has a 1 year low of $1.26 and a 1 year high of $6.87. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.38 and a quick ratio of 2.31. The firm’s 50-day moving average is $1.57 and its two-hundred day moving average is $2.75.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.20). The business had revenue of $8.76 million during the quarter, compared to analysts’ expectations of $8.64 million. Nyxoah had a negative net margin of 443.16% and a negative return on equity of 178.90%. Analysts predict that Nyxoah will post -1.45 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NYXH. Bank of America Corp DE raised its position in shares of Nyxoah by 72.4% during the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company’s stock worth $59,000 after acquiring an additional 3,303 shares in the last quarter. Raymond James Financial Inc. boosted its holdings in Nyxoah by 35.6% in the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock valued at $59,000 after purchasing an additional 3,353 shares in the last quarter. Deutsche Bank AG boosted its holdings in Nyxoah by 40.0% in the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after purchasing an additional 10,000 shares in the last quarter. Citadel Advisors LLC acquired a new position in Nyxoah in the third quarter valued at approximately $98,000. Finally, Shay Capital LLC purchased a new position in Nyxoah in the second quarter valued at approximately $374,000.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.